Sustainable Strategy for the Synthesis of C5-Modified Pyrimidine Nucleosides Utilizing Chloroform–COware Chemistry
Synthesis · 01.01.2026 · 58 (01) · 55-61
DOI: 10.1055/a-2709-7614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthesis, erschienen am 01.01.2026. Verfasst von Mahadev V. Kudalkar und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
CO gas has been a versatile C1 source for carbonylation, amino-carbonylation, and alkoxy-carbonylation. We report an efficient and safer protocol for alkoxy-carbonylation of C5-iodo-derivatives of nucleosides and nucleobases. The modified nucleosides have various applications in chemical biology, medicinal chemistry, and drug discovery. We utilized chloroform and KOH as CO-surrogate for ex situ palladium-catalyzed alkoxy-carbonylation. We explored our protocol for pyrimidine-based nucleosides/nucleobases, which offered good to moderate yields at 80 °C for 24 h. We converted esters to other functional groups such as acids and amides.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Kudalkar, M. V., Kadaskar, P., Sahu, R., Nikam, S. B., Sanghvi, Y. S., & Kapdi, A. (2026). Sustainable Strategy for the Synthesis of C5-Modified Pyrimidine Nucleosides Utilizing Chloroform–COware Chemistry. Synthesis, 58(01), 55-61. https://doi.org/10.1055/a-2709-7614
Vancouver
Kudalkar MV, Kadaskar P, Sahu R, Nikam SB, Sanghvi YS, Kapdi A. Sustainable Strategy for the Synthesis of C5-Modified Pyrimidine Nucleosides Utilizing Chloroform–COware Chemistry. Synthesis. 2026;58(01):55-61. doi:10.1055/a-2709-7614
BibTeX
@article{Kudalkar2026,
author = {Kudalkar, Mahadev V. and Kadaskar, Prajakta and Sahu, Rajesh and Nikam, Sumit B. and Sanghvi, Yogesh S. and Kapdi, Anant},
title = {Sustainable Strategy for the Synthesis of C5-Modified Pyrimidine Nucleosides Utilizing Chloroform–COware Chemistry},
journal = {Synthesis},
year = {2026},
volume = {58},
number = {01},
pages = {55--61},
doi = {10.1055/a-2709-7614}
}
EUVIMED